NASDAQ:PIRSPieris Pharmaceuticals Stock Price, Forecast & News

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PIRS stock has increased by 45.3% and is now trading at $3.24. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pieris Pharmaceuticals.

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Pieris Pharmaceuticals.

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.10. The biotechnology company had revenue of $13.26 million for the quarter, compared to the consensus estimate of $9.43 million. Pieris Pharmaceuticals had a negative net margin of 42.26% and a negative return on equity of 61.01%. View Pieris Pharmaceuticals' earnings history.

3 equities research analysts have issued 1-year price targets for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price. View analysts' price targets for Pieris Pharmaceuticals.

Media coverage about PIRS stock has been trending positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutPieris Pharmaceuticals.

Some companies that are related to Pieris Pharmaceuticals include Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), BIOQUAL (BIOQ), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), Geovax Labs (GOVX), Vitality Biopharma (VBIO), US Stem Cell (USRM) and Protalex (PRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Verastem (VSTM), Amarin (AMRN), Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Omeros (OMER) and Sorrento Therapeutics (SRNE).

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Corriente Advisors LLC (3.41%), State Street Corp (1.77%), Geode Capital Management LLC (1.37%), Acadian Asset Management LLC (1.25%) and Citigroup Inc. (0.79%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il and Christopher P Kiritsy. View institutional ownership trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nuveen Asset Management LLC, Two Sigma Investments LP, Deutsche Bank AG, State Street Corp, BlackRock Inc., GSA Capital Partners LLP, and Ensign Peak Advisors Inc. View insider buying and selling activity for Pieris Pharmaceuticals.

PIRS stock was acquired by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Citigroup Inc., AQR Capital Management LLC, Sigma Planning Corp, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Acadian Asset Management LLC, and Squarepoint Ops LLC. View insider buying and selling activity for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $3.24.

Pieris Pharmaceuticals has a market capitalization of $169.52 million and generates $46.28 million in revenue each year. The biotechnology company earns $-25,470,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.

The official website for Pieris Pharmaceuticals is www.pieris.com.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]